Literature DB >> 20835750

Opportunities for clinical research in meningioma.

Michael A Vogelbaum1, C Leland Rogers, Mark A Linskey, Minesh P Mehta.   

Abstract

Meningiomas, when benign, are commonly treated with surgical resection alone. However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival. In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials. In this review, we discuss a number of trials that were attempted and/or completed by cooperative groups or clinical consortia, and describe areas of clearly unmet need in terms of defining the optimal treatment regimens. Finally, we discuss ongoing efforts to develop new trials to more definitively address important therapeutic questions.

Entities:  

Mesh:

Year:  2010        PMID: 20835750     DOI: 10.1007/s11060-010-0375-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  The accuracy of meningioma grading: a 10-year retrospective audit.

Authors:  J Willis; C Smith; J W Ironside; S Erridge; I R Whittle; D Everington
Journal:  Neuropathol Appl Neurobiol       Date:  2005-04       Impact factor: 8.090

3.  Incidence and clinical features of asymptomatic meningiomas.

Authors:  J Kuratsu; M Kochi; Y Ushio
Journal:  J Neurosurg       Date:  2000-05       Impact factor: 5.115

4.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

6.  Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma.

Authors:  John C Flickinger; Douglas Kondziolka; Ann H Maitz; L Dade Lunsford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

7.  Atypical meningiomas: WHO moved the goalposts?

Authors:  S J Smith; S Boddu; D C Macarthur
Journal:  Br J Neurosurg       Date:  2007-12       Impact factor: 1.596

8.  A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

Authors:  J W Goodwin; J Crowley; H J Eyre; B Stafford; K A Jaeckle; J J Townsend
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

9.  The role of radiotherapy in the treatment of subtotally resected benign meningiomas.

Authors:  R Miralbell; R M Linggood; S de la Monte; K Convery; J E Munzenrider; R O Mirimanoff
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

10.  Grade zero removal of supratentorial convexity meningiomas.

Authors:  T Kinjo; O al-Mefty; I Kanaan
Journal:  Neurosurgery       Date:  1993-09       Impact factor: 4.654

View more
  9 in total

1.  Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Authors:  Andrew D Norden; Keith L Ligon; Samantha N Hammond; Alona Muzikansky; David A Reardon; Thomas J Kaley; Tracy T Batchelor; Scott R Plotkin; Jeffrey J Raizer; Eric T Wong; Jan Drappatz; Glenn J Lesser; Sam Haidar; Rameen Beroukhim; Eudocia Q Lee; Lisa Doherty; Debra Lafrankie; Sarah C Gaffey; Mary Gerard; Katrina H Smith; Christine McCluskey; Surasak Phuphanich; Patrick Y Wen
Journal:  Neurology       Date:  2014-12-19       Impact factor: 9.910

2.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

3.  Efficacy of postoperative radiotherapy for high grade meningiomas.

Authors:  Yunseon Choi; Do Hoon Lim; Kyungil Jo; Do-Hyun Nam; Ho Jun Seol; Jung-Il Lee
Journal:  J Neurooncol       Date:  2014-06-26       Impact factor: 4.130

4.  Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.

Authors:  Brian M Andersen; G Elizabeth Pluhar; Charles E Seiler; Michelle R Goulart; Karen S SantaCruz; Melissa M Schutten; Joyce P Meints; M Gerard O'Sullivan; R Timothy Bentley; Rebecca A Packer; Stephanie A Thomovsky; Annie V Chen; Dominik Faissler; Wei Chen; Matthew A Hunt; Michael R Olin; John R Ohlfest
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

Review 5.  Atypical meningoma: current management dilemmas and prospective clinical trials.

Authors:  Michael D Jenkinson; Damien C Weber; Brian J Haylock; Conor L Mallucci; Rasheed Zakaria; Mohsen Javadpour
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

6.  Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial).

Authors:  Michael D Jenkinson; Damien C Weber; Brian J Haylock; Conor L Mallucci; Rasheed Zakaria; Mohsen Javadpour
Journal:  Neuro Oncol       Date:  2014-07-19       Impact factor: 12.300

7.  Postoperative radiotherapy for meningiomas - a decision-making analysis.

Authors:  Thomas Hundsberger; Paul Martin Putora; Galina Farina Fischer; Detlef Brügge; Nicolaus Andratschke; Brigitta Gertrud Baumert; Davide Giovanni Bosetti; Francesca Caparrotti; Evelyn Herrmann; Alexandros Papachristofilou; Susanne Rogers; Lucia Schwyzer; Daniel Rudolf Zwahlen
Journal:  BMC Cancer       Date:  2022-05-04       Impact factor: 4.638

8.  Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients With Meningiomas.

Authors:  Yuki Kuranari; Ryota Tamura; Noboru Tsuda; Kenzo Kosugi; Yukina Morimoto; Kazunari Yoshida; Masahiro Toda
Journal:  Front Oncol       Date:  2020-11-24       Impact factor: 6.244

9.  EANO guideline on the diagnosis and management of meningiomas.

Authors:  Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.